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Abstract Tumour necrosis factor-alpha (TNFK) is a multi-
functional cytokine that exerts a myriad of biological actions in
numerous different tissues including adipocytes through its two
distinct cell surface receptors. To address the role of each TNF
receptor in the biological actions of TNFK in adipocytes, we have
developed four new preadipocyte cell lines. These were estab-
lished from wild type controls (TNFR1+/+R2+/+) and from mice
lacking TNFR1 (TNFR13/3), TNFR2 (TNFR23/3) or both
(TNFR13/3R23/3). All four new cell lines can fully differentiate
to form mature adipocytes, under appropriate culture conditions,
as judged by cell morphology, expression of multiple adipogenic
markers and the ability to mediate agonist-stimulated lipolysis
and insulin-stimulated glucose transport. In wild type
(TNFR1+/+R2+/+) and TNFR23/3 adipocytes, TNFK stimulated
lipolysis and inhibited insulin-stimulated glucose transport as
well as insulin receptor autophosphorylation. In contrast, these
activities were completely lost in the TNFR13/3R23/3 and
TNFR13/3 cells. Taken together, these studies demonstrate that
TNFK-induced lipolysis, as well as inhibition of insulin-
stimulated glucose transport are predominantly mediated by
TNFR1 and that the presence of TNFR2 is not necessary for
these functions. This new experimental system promises to be
useful in dissecting the molecular pathways activated by each
TNF receptor in mediating the biological functions of TNFK in
differentiated adipocytes.
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1. Introduction
The biological actions of tumor necrosis factor-K (TNFK)
have been studied for over a century. These actions occur in
many cell types and include in£ammation, mitogenesis, di¡er-
entiation, immune modulation and antitumor immunity [1].
TNFK has also been implicated as an important modulator
of energy metabolism, particularly in adipocytes [2]. In these
cells, TNFK regulates the expression of many adipocyte genes
and inhibits the di¡erentiation program [3]. It has also been
demonstrated to directly interfere with glucose homeostasis
and lipid metabolism in adipose tissue and contribute to the
development of insulin resistance in obesity and type 2 dia-
betes [2,4,5].
At the molecular level, the cellular actions of TNFK are
mediated by two distinct receptors: type 1 (TNFR1; a 55
kDa peptide in rodents and 60 kDa in humans), and type 2
(TNFR2; 75 kDa in rodents and 80 kDa in humans) [6]. Both
these receptors are expressed ubiquitously and oligomerize
upon binding of the trimeric ligand. While the extracellular
domains of these two receptors exhibit some sequence homol-
ogy, their intracellular or cytoplasmic domains appear to be
quite dissimilar [6]. This is thought to be indicative of the
existence of distinct signalling pathways. The biological func-
tions mediated by each TNF receptor have been studied with
the aid of type-selective ligands [7^9] or antibodies that act as
agonists or antagonists [10]. For example, human TNFK has
been reported to be selective for murine TNFR1 (p55) and as
a result has been used to demonstrate the involvement of
TNFR1 in a variety of cellular systems including adipocytes
[7,9,11]. Similarly, human ligand mutants have been devel-
oped with di¡erential a⁄nity for hTNFR1 or hTNFR2 [8].
Finally, type selective antibodies, with either agonistic or an-
tagonistic activity have been widely utilized to understand the
signalling and biology of the di¡erent TNF receptors [11,12].
While these experimental systems have provided a vast
amount of valuable information, their use has some limita-
tions, especially in long term studies that arise from di¡er-
ences in a⁄nities and/or stability in di¡erent cell types. This
has been particularly problematic in studies targeting fat-la-
den adipocytes. Furthermore, since receptor hetero-complex-
ing may be a prerequisite for some TNFK-induced signals,
extracellular targeting of one receptor may not prevent the
engagement of its intracellular domains in heterocomplexes
and subsequent involvement in signal generation.
Recently, targeted null mutations have been introduced into
the murine genes of both TNF receptors [13^15]. These stud-
ies have demonstrated that both receptors are critically in-
volved in the establishment of host defense and have provided
excellent models for studying the biological capabilities each
TNF receptor. The single TNF receptor de¢cient mice have
been critical in demonstrating that TNFR1 plays a dominant
role in mediating endotoxic shock, LPS- and TNF-induced
toxicity [13,14] but plays a protective role in L. monocyto-
genes-induced infection [13,14]. It is also involved in the de-
velopment of lymphoid tissue [16] and pathologies such as
collagen-induced arthritis [17]. Conversely, it is TNFR2 that
suppresses TNF-induced in£ammatory responses [15] but also
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required for TNF-induced T-cell toxicity, tissue necrosis [18],
the migration of epidermal Langerhans cells, initiation of cu-
taneous immune responses [19] and the development of exper-
imental cerebral malaria [20].
In relation to metabolic functions, a number of recent stud-
ies using receptor- or ligand-de¢cient mice have addressed the
in vivo role of TNFK signalling in obesity and insulin resis-
tance [21^24]. These studies have demonstrated that the ab-
sence of TNFK function a¡ords considerable protection from
obesity-related insulin resistance [21,22]. While the dominant
mediator of this TNFK function appears to be TNFR1, a role
for TNFR2 has not been ruled out. Genetically obese (ob/ob)
mice lacking TNFR1, but not TNFR2, showed improved in-
sulin sensitivity [23], a study reported this to be the case only
in TNFR2-de¢cient mice fed a high-fat diet [24]. In an at-
tempt to understand the exact role of each TNF receptor at
the cellular and molecular level, we have developed a new in
vitro experimental system derived from embryos of TNF re-
ceptor knockout mice. The use of adipocyte cell lines with
genetic alterations has not been widely utilized due to chal-
lenges in developing these experimental systems. This has lim-
ited the molecular characterization of the biology of this cy-
tokine particularly in cases where the adipocyte is the primary
target. Here, we report our initial characterization of these
preadipocyte cell lines, which lack TNFR1, TNFR2, or
both, and compare their metabolic responses to wild type
control cells with intact receptors.
2. Materials and methods
2.1. Materials and reagents
Recombinant murine TNFK was purchased from Genzyme (Cam-
bridge, MA). 2-Deoxy-D-[1,2-3H]glucose (40 Ci/mmol, 1 mCi/ml) and
[K-32P]dCTP (6,000 Ci/mmol, 20 mCi/ml) were from Amersham Life
Science, USA and Dupont-NEN (Boston, MA), respectively. The
thiazolidinedione, BRL49653 (FW 473.5), was kindly provided by
Dr. Hideko Tanaka (Mitsubishi Chemical Corp., Japan).
2.2. Establishment of preadipocyte cell lines
Mice de¢cient in TNFR1, TNFR2 or both TNFR1 and R2 and the
wild type controls were previously reported [21]. Embryos from these
mice were eviscerated and used to isolate adherent cells. Fibroblast
cell lines were then developed using the previously described 3T3
protocol [25]. This protocol was continued for approximately 15^25
passages, by which time propagating cells had entered and recovered
from the growth retardation phase termed ‘crisis’. Following crisis
each ¢broblastic cell line was expanded and multiple aliquots frozen
in DMEM containing 10% Cosmic calf serum and 10% DMSO. Eight
independent cell lines (two from each genotype) were then tested
for their di¡erentiation potential following treatment with the adipo-
genic agents as described below. Although, four cell lines (one of
each genotype) failed to produce any adipocytes even under the stron-
gest adipogenic stimuli, two cell lines (wt and TNFR13=3) produced
s 85% adipocytes. The poorly di¡erentiating lineages yielding 6 80%
adipocytes (TNFR13=3R23=3 and TNFR23=3) were further im-
proved by two consecutive rounds of population cloning [26] produc-
ing 30^50 clones from each parental cell line. Each clone was then
tested for its adipogenic potential and those producing s 80% adipo-
cytes were further expanded and stored. Finally, the presence and/or
absence of each TNF receptor was re-con¢rmed in each cell line by
genotyping [21] and Northern blotting (see below and Fig. 2).
2.3. Cell culture and adipocyte di¡erentiation
Preadipocytes were maintained and propagated in Dulbeco’s Mod-
i¢cation of Eagle’s Media (DMEM), containing high glucose, L-glu-
tamine, pyridoxine HCl, no sodium pyruvate and supplemented with
10% bovine calf serum (Hyclone), 50 U/ml penicillin and 50 Wg/ml
streptomycin. Di¡erentiation of preadipocytes was achieved by a
modi¢cation of the procedure described for 3T3-L1 cells [25]. Brie£y,
cells were seeded and grown to 80^90% con£uence in DMEM supple-
mented with 10% forti¢ed bovine calf serum (FBS or Cosmic calf
serum0, Hyclone). Di¡erentiation was then initiated (day 0) by in-
cubation in induction medium (DMEM supplemented with 10% FBS,
50 U/ml penicillin, 50 Wg/ml streptomycin, 1 WM dexamethasone,
0.5 mM isobutylmethy xanthine (IBMX), 1 WM BRL49653 and 5 Wg/
ml insulin). Following a 4-day induction treatment (two 48-h incuba-
tions), the medium was changed to a post-induction media (in-
duction media without dexamethasone and IBMX) for an additional
4 days (two 48-h incubations). Thereafter, the medium was replaced
every other day with DMEM containing 10% FBS and 5 Wg/ml of
insulin. Unless otherwise stated, cells were used for experiments on
day 16 after the start of induction.
2.4. Determination of stimulated lipolysis
Intracellular lipolysis in fully di¡erentiated adipocytes was assessed
by the extent of glycerol release from adherent cells seeded in 35 mm
six-well plates. Adipocyte monolayers were washed and incubated in
complete serum free medium (with L-glutamine and albumin, Medi-
atech Cellgrow) þ 10 ng/ml TNFK for 20 h at 37‡C. This was fol-
lowed by a 4-h incubation in fresh complete serum free medium
þ 10 ng/ml TNFK or 1 mM dibutyryl-cAMP. The glycerol concentra-
tion was determined in heat-inactivated conditioned media using the
enzyme-based GPO trinder reagent kit from Sigma (St. Louis, MO,
USA). Cell monolayers were then digested in 0.1% SDS for protein
quantitation using the BioRad DC protein assay based on the Lowry
method (BioRad Laboratories, CA).
2.5. Determination of glucose uptake and insulin-stimulated IR
phosphorylation
For glucose uptake experiments, fully di¡erentiated adipocytes were
washed and serum starved for 24 h prior to insulin stimulation. Cell
monolayers, were then washed three times with warm Krebs^Ringer
HEPES bu¡er (KRH: 120 mM NaCl, 5 mM KCl, 1 mM KH2PO4,
0.6 mM MgSO4, 1 mM CaCl2, 20 mM HEPES, pH 7.5 and 0.5%
bovine serum albumin) and incubated for 30 min in 1 ml (per 35 mm
well) KRH þ 1 Wg/ml insulin at 37‡C. Isotope-labelled glucose uptake
was initiated during the last 10 min by the addition of 2-deoxy-D-
[1,2-3H]glucose (1 WCi/ml). The reaction was terminated by immedi-
ately removing the medium and washing cell monolayers three times
with chilled KRH. Cells were removed in 1 ml SDS (0.1%) and the
radioactivity determined in a 0.8 ml aliquot by liquid scintillation
counting. The remaining digest was used for protein quanti¢cation
using the BioRad DC protein assay based on the Lowry method
(BioRad Laboratories, CA, USA). Non-speci¢c uptake was deter-
mined by incubating with 50 WM cytochalsin B for 10 min prior to
the addition of radioactivity [29]. Insulin receptor autophosphoryla-
tion was examined in the presence or absence of TNFK (10 ng/ml) as
previously described. Immunoblotting was performed using a 1:1000
dilution of a monoclonal anti-phosphotyrosine (PY20) or a 1:300
dilution of the polyclonal anti-murine IRL antibody (gift from C.R.
Kahn), followed by horseradish peroxidase (HRP)-conjugated anti-
mouse or anti-rabbit IgG antibodies (1:2500 dilution), respectively.
Immunoreactive bands were visualized using an enzyme chemilumi-
nescence (ECL) kit (Amersham Life Science) and pTyr/protein ratios
were determined by densitometrical analysis using NIH Image soft-
ware.
2.6. Statistical analysis
Data is presented as means þ S.E.M. of triplicates. Two-tailed, two-
sample, equal variance Student t-tests were used to assess statistical
signi¢cance where P6 0.05 was the accepted level of statistical signi¢-
cance.
3. Results and discussion
3.1. TNFR-de¢cient preadipocyte cell lines
To address the role of each TNF receptor in mediating the
metabolic actions of TNFK in adipocytes, we have established
three preadipocyte cell lines, which carry targeted null muta-
tions in the genes encoding TNFR1, TNFR2, both TNFR1
and TNFR2. A fourth, wild type cell line was also generated
with the same genetic background. Prior to di¡erentiation, all
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of these cells appeared to be morphologically indistinguish-
able from murine ¢broblasts as illustrated in Fig. 1 (left
column of photomicrographs). The di¡erentiation potential
of each cell type was then tested as described in Section 2.
The photomicrographs in Fig. 1 (center and right columns)
demonstrate that following adipogenic treatment, all four new
cell lines were capable of accumulating lipid droplets (yielding
s 90% adipocytes), thereby exhibiting the morphological
characteristics of adipocytes. Lipid accumulation in these cells
is also readily detectable by Oil Red O staining (Fig. 1, right
column). In contrast, when the same cells were grown and
maintained at con£uency, in medium lacking adipogenic
agents, very few (6 0.5%), cells adopted the lipid-laden phe-
notype (Fig. 1, left column).
3.2. Adipocyte-speci¢c gene expression in TNFR de¢cient cells
During adipocyte di¡erentiation, a number of genes are
di¡erentially expressed. Some, such as those involved in lipid
synthesis and storage, are related speci¢cally to the adipogenic
phenotype [30]. We therefore investigated the expression pat-
tern of several genes in our new preadipocytes during the
course of di¡erentiation. Fig. 2 shows the gene expression
pattern in TNFR-de¢cient cells following 16 days of treat-
ment with (+) or without (3) adipogenic agents. In all four
cell types, adipogenic treatment clearly resulted in the expres-
sion of classic adipocyte speci¢c markers such as aP2 (adipo-
cyte fatty acid-binding protein), PPARQ (peroxisome prolifer-
ator-activated receptor Q), C/EBPK (CAAT/enhancer binding
protein), Glut4 (insulin sensitive glucose transporter) and
adipsin (a protease secreted from adipocytes). Conversely,
the maintenance of cells at con£uence or growth arrest did
not induce the expression of the same genes. The expression
levels and patterns of these genes are clearly comparable to
those observed in the commonly used preadipocyte cell line
3T3-L1 treated with the same protocol. The same RNA blots
were also used to con¢rm the expression of the TNFR(s) in
the respective cell types. As reported previously [23], the level
of receptor expression in the single receptor de¢cient cells
appeared comparable to that seen in wild-type cells (Fig. 2).
Thus the absence of one TNF receptor does not seem to alter
the endogenous expression level of the other.
We next investigated the time course of gene expression
throughout the adipogenic treatment and compared this to
the same treatment of 3T3-L1 cells. Each of the cell lines
exhibited di¡erentiated-dependent gene expression during the
16-day treatment and this gene expression pattern is clearly
comparable to that observed in 3T3-L1 cells (data not shown).
The level of adipocyte-speci¢c gene expression reached a max-
imum by day 14, where these cells could be considered mature
adipocytes. Therefore, 16-day old adipocytes were used in all
the subsequent experiments described in this report. Finally,
our data also suggests that the absence of one or both
TNFR(s) does not alter the ability or e⁄ciency of these pre-
adipocytes to di¡erentiate into mature adipocytes. This is con-
Fig. 1. Morphological features of cultured TNFR-de¢cient cells. Photomicrographs of TNFR-de¢cient preadipocytes (left), fully di¡erentiated
adipocytes unstained (center) and stained with Oil red O (right). All lines appear to be morphologically indistinguishable from murine preadipo-
cytes and upon stimulation, exhibit typical adipocyte morphology.
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sistent with the observation that cultured adipocytes do not
express detectable levels of TNFK [28] and mice de¢cient in
one or both of TNF receptors exhibit no obvious alteration in
adipose tissue development [23].
3.3. Agonist-stimulated lipolysis in TNFR de¢cient adipocytes
One of the primary biological functions of adipocytes is to
adjust their lipid storage according to the physiological energy
requirements of the organism. When extra calories are re-
quired, adipocyte intracellular triglyceride stores are metabo-
lized to glycerol and fatty acids for further oxidation, a pro-
cess termed lipolysis. This process is regulated by adrenergic
stimulation and mediated by a cAMP-dependent pathway
[31]. To further evaluate the adipocyte phenotype, we next
tested the lipolytic capacity of the TNFR de¢cient adipocytes.
Fig. 3A shows that following di¡erentiation, all four of the
new preadipocyte cell lines respond to both dibutyryl-cAMP
(a membrane permeable, hydrolysis-resistant analogue of
cAMP) and the non-speci¢c adrenergic receptor agonist iso-
proterenol. These data demonstrate that all of the adipocyte
cell lines possess the appropriate lipolytic machinery that is
required to respond to stimulation directly by dibutyryl-
cAMP or via adrenergic receptors.
Since TNFK itself can act as a lipolytic agent in wild-type
adipocytes [2,32], we next examined the ability of TNFK to
induce lipolysis in each cell type. Fully di¡erentiated adipo-
cytes were treated with or without TNFK (10 ng/ml) for 24 h
and the amount of glycerol released into the culture media
was determined (Fig. 3B). As expected, TNFK produced a
lipolytic response in wild-type adipocytes. This e¡ect was
completely absent in adipocytes lacking TNFR1 or both func-
tional receptors but preserved in TNFR2-de¢cient cells. These
experiments demonstrate that TNFK-stimulated lipolysis is
intact only in those adipocytes expressing functional
TNFR1, indicating that this receptor is the obligatory medi-
ator of this action of TNFK.
Fig. 2. Adipocyte-speci¢c gene expression during di¡erentiation of
TNFR-de¢cient preadipocytes. Total RNA was extracted from cells
of each genotype following 16 day treatment with (+) or without
(3) adipogenic agents (as described in Section 2) and expression of
the indicated genes examined by Northern blot analysis as previ-
ously described [27,28].
Fig. 3. Stimulated lipolysis in TNFR-de¢cient adipocytes. Di¡erenti-
ated adipocytes from each genotype were cultured in the absence
(basal) or presence of (A) dibutyryl cAMP (1 mM for 4 h) or iso-
proterenol (1WM for 4 h) or (B) TNFK (10 ng/ml for 24 h). Condi-
tioned media were then collected over the last 4-h incubation and
assayed for glycerol content. Values represent means þ S.D. of tripli-
cates. The basal lipolysis values in (B) were 3.5 þ 0.7, 4.1 þ 1.9,
16.4 þ 0.8 and 11.6 þ 1.8 Wg glycerol released/mg protein/4 h from
TNFR-wt, TNFR13=3R23=3, TNFR13=3 and TNFR23=3 cells, re-
spectively.
Fig. 4. E¡ect of TNFK on insulin stimulated glucose uptake in
TNFR de¢cient adipocytes. 2-Deoxy-glucose uptake was determined
in di¡erentiated adipocytes of each genotype. TNFK treatment in-
volved a 24 h exposure to 10 ng/ml TNFK followed by stimulation
with 1 Wg/ml insulin for 30 min. Values represent means þ S.D. of
triplicates. The basal glucose uptake in each cell type were
3085 þ 514, 3826 þ 111, 2058 þ 271 and 1157 þ 132 cpm/mg protein
for TNFR-wt, TNFR13=3R23=3, TNFR13=3 and TNFR23=3 cells,
respectively. * indicates P6 0.05 when compared to the insulin-
stimulated controls.
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3.4. Insulin-stimulated glucose uptake in TNFR de¢cient
adipocytes
Another well-established action of TNFK in adipocytes, is
that of inhibiting insulin-stimulated glucose uptake
[2,29,33,34]. To investigate whether this in vitro system could
be used to identify the TNFR responsible for mediating this
action in adipocytes, we next investigated the e¡ect of TNFK
on insulin-stimulated glucose uptake in the TNFR-de¢cient
cell lines. Fully di¡erentiated adipocytes of each genotype
were treated with or without TNFK (10 ng/ml for 24 h)
and/or insulin (1 Wg/ml for 30 min) and the rate of 2-deoxy-
D-[1,2-3H]glucose uptake was determined over a 10 min period
(Fig. 4). As reported for the 3T3-L1 adipocytes [29], all four
of the new adipocyte cell lines clearly responded to insulin by
increasing their rate of glucose uptake. This suggests that the
insulin signaling pathways, which regulate glucose uptake are
also intact in all four cell lines. In these cells, the basal rate of
glucose uptake is not signi¢cantly altered by the presence of
TNFK alone. However, in cells expressing functional TNFR1,
namely the wild-type and TNFR23=3 adipocytes, pretreat-
ment with TNFK resulted in signi¢cant inhibition of insulin-
stimulated glucose uptake (18 and 39% inhibition in wild-type
and TNFR23=3 adipocytes, respectively, P6 0.05). These re-
sults indicate that inhibition of insulin-stimulated glucose
transport by TNFK requires the presence of intact TNFR1
signalling.
3.5. Insulin-stimulated IR phosphorylation in TNFR de¢cient
adipocytes
Although TNFK has been demonstrated to inhibit tyrosine
phosphorylation of insulin receptor (IR) [33,35], it remains
unclear whether this action is solely attributed to the activity
of TNFR1 [11,12]. We have therefore investigated the action
of this cytokine on IR-phosphorylation in our new cells. In-
sulin receptors (IR) were immunoprecipitated from di¡erenti-
ated adipocytes of each genotype after treatment with or with-
out TNFK (10 ng/ml) and/or insulin (1.5 Wg/ml for 100 s). Fig.
5 illustrates the immunoblots obtained from these immuno-
precipitates. Immunoblotting with antibodies speci¢c to IRL
demonstrates that all four cell types express signi¢cant levels
of insulin receptor. This observation is entirely consistent with
the insulin responsiveness shown in Fig. 4. Furthermore, the
expression of this protein is not downregulated by TNFK
treatment in this experimental system. Probing the same blots
with phosphotyrosine (pTyr)-speci¢c antibodies further shows
that a marked increase in IR tyrosine phosphorylation follow-
ing insulin stimulation is evident in all cells. This is also a
consistent observation of insulin responsiveness in these cells.
Finally, TNFK-induced inhibition of IR-pTyr is apparent only
in wild-type (3.9 þ 0.4 versus 2.5 þ 0.3 pTyr/prot signal) and
TNFR23=3 (2.8 þ 0.03 versus 1.1 þ 0.4 pTyr/prot signal)
adipocytes, but not in TNFR13=3R23=3 (2.5 þ 0.4 versus
2.5 þ 0.4 pTyr/prot signal) or TNFR13=3 (1.9 þ 0.3 versus
1.7 þ 0.3 pTyr/prot signal) cells. This suggests that endogenous
levels of TNFR1 alone can mediate inhibition of IR auto-
phosphorylation by TNFK. However, the action of endoge-
nous levels of TNFR2 alone, if any, is undetectable under
these experimental conditions.
4. Conclusions
Adipocytes play a critical role in systemic energy homeo-
stasis by producing molecules such as leptin, PAI-1 and sev-
eral cytokines including TNFK and IL-6 that in£uence many
key metabolic pathways [36]. Interestingly, several of these
molecules also regulate the expression and/or production of
each other through complex signalling networks [37,38]. Al-
terations in these aspects of adipocyte biology appear to be
Fig. 5. E¡ect of TNFK on insulin-stimulated receptor tyrosine phosphorylation in TNFR-de¢cient adipocytes. Insulin receptors (IR) were im-
munoprecipitated from control and insulin-stimulated adipocytes that were pre-treated with or without TNFK (10 ng/ml for 72 h). Antibodies
speci¢c for phosphotyrosine (pTyr) or insulin receptor beta subunit (IRL) were used for immunoblotting.
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important in several disease states, including obesity, type 2
diabetes and cardiovascular disease. For example, TNFK can
regulate leptin production from the adipose tissue and con-
tribute to obesity-associated hyperleptinemia [37]. Similarly,
TNFK stimulates PAI-1 expression in adipocytes and appears
to be the dominant signal for increased PAI-1 production in
obesity and potentially contribute to increased risk for cardio-
vascular disease [39]. Furthermore, TNFK has well-docu-
mented e¡ects on lipid and glucose metabolism by regulating
lipolysis, lipid biosynthesis and insulin sensitivity [2,32].
Therefore, understanding the molecular mechanisms of
TNFK action in adipocytes might provide important insights
into several pathophysiological states. In an attempt to study
the biological functions mediated by each TNF receptor in
adipocytes, we have developed a new cellular experimental
system by establishing preadipocyte cell lines lacking one or
both TNF receptors. Biochemical examination of these cells
demonstrates that these do di¡erentiate into bona ¢de adipo-
cytes based on all morphological, molecular and functional
characteristics studied. Using these cells, we have also exam-
ined the role of TNFR1 and TNFR2 in two critical metabolic
activities of TNFK in adipocytes. These studies demonstrate
that stimulation of lipolysis, inhibition of insulin receptor sig-
nalling and insulin-stimulated glucose uptake by TNFK re-
quires the presence of TNFR1. These observations, together
with the existing data obtained through the use of receptor
selective ligands or antibodies [7,12] indicate TNFR1 as the
primary mediator of TNFK-induced insulin resistance in adi-
pocytes and obesity [23]. In conclusion, these mutant preadi-
pocyte cell lines represent a new experimental system, which
should prove to be instrumental in future mechanistic and
structure-function studies of TNF receptors in adipocytes.
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